BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

OrbiMed raised $3.5 billion across a trio of private funds. The firm has commitments of $1.5 billion for OrbiMed Private Investments VIII, which will invest $10-$100 million in about 40 North American and European biotech,...
BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

Novavax Inc. (NASDAQ:NVAX) said in its 4Q20 earnings report that it is discussing COVID-19 vaccine NVX-CoV2373 with FDA and may submit a request for emergency use authorization of candidate next quarter. The biotech announced on...
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The candidate is under FDA and EMA review.  Sanofi is...
BioCentury | Feb 19, 2021
Finance

Canada’s Sagard tops off royalty fund at $725M, beating goal

Just over a year after the first close of Sagard’s royalty fund, the firm has found that enthusiasm from LPs ran higher than expected, driving it to a final close above its target. Canadian firm...
BioCentury | Feb 18, 2021
Regulation

Feb. 18 Quick Takes: Label expansion for Entresto; plus Amgen, Sesen, BeiGene, Cortexyme and more

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA approved Entresto sacubitril/valsartan to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure. The approved population includes heart failure patients with...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for...
BioCentury | Feb 9, 2021
Regulation

Survival projections aren’t enough to sway ODAC to recommend Keytruda for new TNBC indications

FDA and its Oncology Drugs Advisory Committee want more survival data before supporting an accelerated approval of Keytruda as an adjuvant and neoadjuvant therapy for triple-negative breast cancer — a...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration.  The agency backed Kesimpta ofatumumab, an auto-injectable anti-CD20 mAb from Novartis AG (NYSE:NVS; SIX:NOVN),...
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

Three months after its lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc. and  recapitalizing through a $110 million PIPE led by Xontogeny affiliate Perceptive Advisors....
Items per page:
1 - 10 of 10604
BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

OrbiMed raised $3.5 billion across a trio of private funds. The firm has commitments of $1.5 billion for OrbiMed Private Investments VIII, which will invest $10-$100 million in about 40 North American and European biotech,...
BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

Novavax Inc. (NASDAQ:NVAX) said in its 4Q20 earnings report that it is discussing COVID-19 vaccine NVX-CoV2373 with FDA and may submit a request for emergency use authorization of candidate next quarter. The biotech announced on...
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The candidate is under FDA and EMA review.  Sanofi is...
BioCentury | Feb 19, 2021
Finance

Canada’s Sagard tops off royalty fund at $725M, beating goal

Just over a year after the first close of Sagard’s royalty fund, the firm has found that enthusiasm from LPs ran higher than expected, driving it to a final close above its target. Canadian firm...
BioCentury | Feb 18, 2021
Regulation

Feb. 18 Quick Takes: Label expansion for Entresto; plus Amgen, Sesen, BeiGene, Cortexyme and more

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA approved Entresto sacubitril/valsartan to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure. The approved population includes heart failure patients with...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for...
BioCentury | Feb 9, 2021
Regulation

Survival projections aren’t enough to sway ODAC to recommend Keytruda for new TNBC indications

FDA and its Oncology Drugs Advisory Committee want more survival data before supporting an accelerated approval of Keytruda as an adjuvant and neoadjuvant therapy for triple-negative breast cancer — a...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration.  The agency backed Kesimpta ofatumumab, an auto-injectable anti-CD20 mAb from Novartis AG (NYSE:NVS; SIX:NOVN),...
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

Three months after its lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc. and  recapitalizing through a $110 million PIPE led by Xontogeny affiliate Perceptive Advisors....
Items per page:
1 - 10 of 10604